Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients

ClinicalTrials.gov ID: NCT00122330

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00122330. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-Blind, and Placebo-Controlled Study Using Eculizumab in Transfusion Dependent PNH Patients

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective is to evaluate the safety and efficacy of eculizumab in transfusion dependent patients with hemolytic PNH.

Study identification

NCT ID
NCT00122330
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Enrollment
75 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 2004 (Type not available)
Primary completion
Not listed
Completion
Jan 2006 (Type not available)
Last update posted
Dec 4, 2006

2004 – 2006

United States locations

U.S. sites
16
U.S. states
11
U.S. cities
15
Facility City State ZIP Site status
City of Hope National Medical Center, Div. of Hematology & Bone Marrow Transplant Duarte California 91010-3000 —
University of California at Los Angeles Los Angeles California 90024 —
Scripps Cancer Center San Diego California 92121 —
Stanford University Medical Center, Division of Hematology Stanford California 94305-5821 —
Hartford Hospital, Cancer Clinical Research Office Hartford Connecticut 06102 —
Cleveland Clinic, Dept. of Clinical Research Weston Florida 33331 —
Indiana University Cancer Pavilion, Div. of Hematology-Oncology, Hematological Malignancy Program/Immunology Indianapolis Indiana 46202 —
Johns Hopkins University Medical Center Baltimore Maryland 21205 —
National Heart, Blood, and Lung Institute, National Institutes of Health Bethesda Maryland 20892 —
Massachusetts General Hospital Boston Massachusetts 02114 —
Washington University School of Medicine, Dept. of Internal Medicine/Division of Hematology St Louis Missouri 63110-1093 —
NYU Clinical Cancer Center New York New York 10016 —
Memorial Sloan Kettering Cancer Center New York New York 10021 —
Duke University Health System, Division of Cell Therapy, Heme Malignancies Program Durham North Carolina 27710 —
Cleveland Clinic Foundation Cleveland Ohio 44195 —
Presbyterian Medical Center, PENN Comprehensive Hemophilia & Thrombosis Program Philadelphia Pennsylvania 19104 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00122330, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 4, 2006 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.